“Mich. lawmaker introduces baby-sitting bill - detnews.com” plus 4 more

Mich. lawmaker introduces baby-sitting bill - detnews.com
Too-Fat Baby Denied Health Care - Eyewitness News
Expert: Quicker care could have saved baby - Times Union
Celebrity Baby Blog Newsletter - Celebrity Baby Blog
Teva (TEVA): Baby-boomers give boost to generics - Bloggingstocks.com

Mich. lawmaker introduces baby-sitting bill - detnews.com

Posted: 14 Oct 2009 01:36 PM PDT

Associated Press

Lansing -- A Michigan lawmaker has crafted a bill that would exempt baby-sitting from the state's day care regulations.

Republican Rep. Brian Calley of Portland introduced the bill Tuesday in Lansing.

It comes after the Michigan Department of Human Services ordered a Barry County woman last month to stop watching her friend's three children before they got on their school bus.

Gov. Jennifer Granholm has instructed agency Director Ismael Ahmed to work with the Legislature to change a law so people performing the same free baby-sitting service as Irving Township's Lisa Snyder won't have to get day care licenses.

Under the bill, people who baby-sit a nondependent child would be exempt from day care rules if they weren't engaged in a child care business.

This content has passed through fivefilters.org.

Too-Fat Baby Denied Health Care - Eyewitness News

Posted: 14 Oct 2009 12:03 PM PDT

This content has passed through fivefilters.org.

This posting includes an audio/video/photo media file: Download Now

Expert: Quicker care could have saved baby - Times Union

Posted: 14 Oct 2009 11:56 AM PDT

TROY -- A specialist in pediatrics testified Tuesday that 4-month-old Matthew Thomas, whose father is accused of killing him, could have survived if the boy arrived at the hospital sooner.

''He was an extremely sick boy when he came to the hospital,'' said Dr. Carole Jenny of the Hasbro Children's Hospital in Providence, R.I.

''Had they had got him to the hospital the night before when there was first signs of difficulty breathing he probably could have been saved,'' continued Jenny, an expert who reviewed the case for the Rensselaer County district attorney's office.

Jenny was the prosecution's last witness in the second-degree murder trial of 27-year-old Adrian Thomas. He is accused of throwing the baby down hard on a bed over three separate days in September 2008. Prosecutors said Thomas was venting anger at the infant's mother, Willhemina Hicks.

According to trial testimony, Thomas and Hicks said the boy was having trouble breathing the night of Sept. 20, and talked of taking him to the hospital but instead decided to do so next morning. That morning Hicks, who was unaware of Thomas' alleged abuse, found the baby unresponsive in his crib and called 911. He was declared brain dead shortly after arriving at the hospital.

On Tuesday Hicks dabbed tears through much of the medical testimony about her son.

Prosecutors rested their case later Tuesday and the defense will begin this morning calling its witnesses, including other medical experts.

Defense attorney Ingrid Effman told jurors in opening arguments that sepsis, a serious bacterial infection of the blood, caused Matthew's death and could have also caused the swelling of the brain.

This content has passed through fivefilters.org.

Celebrity Baby Blog Newsletter - Celebrity Baby Blog

Posted: 14 Oct 2009 09:33 AM PDT

Post to:

This content has passed through fivefilters.org.

Teva (TEVA): Baby-boomers give boost to generics - Bloggingstocks.com

Posted: 14 Oct 2009 09:25 AM PDT

"The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests growth stock specialist Stephen Leeb.

In The Complete Investor, he explains, "That's because they're leveraged to demographic realities, and in particular to the tide of aging baby boomers," Here, he reviews on portfolio holding -- Teva Pharmaceuticals (NASDAQ: TEVA).

Leeb says, "Israel-based Teva Pharmaceutical is the world's largest manufacturer of generic drugs. Capitalized at $49 billion, Teva pulled in some $11 billion in revenues in 2008, with generic drugs contributing more than two-thirds of those sales.

"Baby-boomers are spending increasing amounts of money on prescription drugs. Further, generics sell for a lot less than their brand-name counterparts and thus are more likely to be better covered by insurance, actually benefit from economic downturns as consumers cut back on spending.

"In general, demand for drugs is relatively inelastic, while a growing number of brand-name medications are now coming off patent. This puts Teva on track for long-term earnings growth of close to 20% a year, a torrid pace in any economy.

"In its latest earnings report, the company reported second-quarter profits of $742 million excluding onetime costs, a 25% increase over year-earlier results.And rare today, its U.S. sales were particularly strong-up 36% and accounting for 63% of all sales.

"Teva's new generic version of the hyperactivity drug Adderall helped revenues grow by 20 percent, to $3.4 billion, in the second quarter.

"In addition, sales of Copaxone, Teva's brand-name multiple sclerosis drug, which accounts for around 20% of company-wide revenues, were stronger than expected.

"Also aiding results was last year's $7.4 billion acquisition of Barr Pharmaceuticals, which Teva's management now expects will lead to savings of $500 million next year rather than the $300 million initially projected. In all, management expects profit growth next year of 35%.

"In a sector full of question marks, generic drugs, and thus industry leader Teva, are as close to a surefire winner as you can get. Trading at less than 12 times expected 2010 earnings, with a PEG of 0.6, shares are a bargain."

Steven Halpern's TheStockAdvisors.com offers a free daily overview of the favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.

This content has passed through fivefilters.org.